Ascendis Pharma extends trial of growth hormone in adults

240 adults will continue receiving treatment with weekly growth hormone produced by Ascendis in a new study to determine the long-term efficacy and safety profile of the drug.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by mikkel aabenhus hemmingsen, translated by catherine brett

Ascendis Pharma will continue to test growth hormone lonapegsomatropin in adults to collect further data on the drug's efficacy and safety when used for a longer period.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading